Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 38,328,860
  • Shares Outstanding, K 105,460
  • Annual Sales, $ 4,104 M
  • Annual Income, $ 636 M
  • 36-Month Beta 1.80
  • Price/Sales 8.10
  • Price/Book 8.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
349.24 +1.47%
on 01/09/17
391.49 -9.48%
on 12/27/16
-27.42 (-7.18%)
since 12/23/16
3-Month
325.35 +8.92%
on 11/04/16
452.96 -21.77%
on 11/14/16
-9.17 (-2.52%)
since 10/21/16
52-Week
325.35 +8.92%
on 11/04/16
482.27 -26.52%
on 01/25/16
-128.63 (-26.63%)
since 01/22/16

Most Recent Stories

More News
Biotech Stocks Under Scanner -- Kite Pharma, BioPharmX, OvaScience, and Regeneron Pharma

Ahead of today's trading session, Stock-Callers.com draws investors' attention to four Biotech equities to see how they have fared at the close: Kite Pharma Inc. (NASDAQ: KITE), BioPharmX Corp. (NYSEMKT:...

Key FDA Events to Watch Out for in Q1

Two important regulatory events scheduled in the first quarter of 2017.

Stock Market News for January 11, 2017

The Nasdaq registered its fourth record close in a row on Tuesday, thanks to gains in healthcare stocks

Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche’s, Sanofi and Regeneron Pharmaceuticals

Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit

Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.

Company News for January 09, 2017

Companies in the News are: T,TWX,GPS,RT,REGN

The FDA Approved Fewer Drugs in 2016: Here's Why

Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regeneron from Selling their Cholesterol Drug in the US

LONDON, UK / ACCESSWIRE / January 9, 2017 / Active Wall St. blog coverage looks at the headline from Amgen Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi SA (NYSE: SNY)....

Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 366.79
1st Resistance Point 360.58
Last Price 354.36
1st Support Level 351.16
2nd Support Level 347.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.